Different tablet dosage forms were prepared to be administered for patients with dysphagia (swallowing difficulties) like buccal, sublingual and orodispersible tablets, however, they possesses certain constrains like taste masking difficulties, limitations in drug and dose selection and friability. Hence, in an attempt to overcome these constrains, a new easily swallowed immediate release tablets containing (160mg) Valsartan were prepared, and designed to be slippery upon contact with saliva giving an easy swallowing of the intact tablet (without water) with efficient taste masking effect, thus, they called Oroslippery tablets (OSTs). Core tablets were prepared by direct compression using different superdisintegrants, followed by dipping in special coating dispersion containing different proportion of kollicoat IR (film former) and xanthan gum (slipperiness inducer) at different coating levels. These OSTs were optimized for their physical properties, in-vitro disintegration and release in addition to in-vivo slipperiness and taste masking effect. It was found that F12 containing 6% crosscarmellose sodium double coated with 15% kollicoat IR and 0.3% xanthan gum possessed a good mechanical strength (hardness=5.69±0.58 Kg/cm 2 , friability=0.09%±0.79), suitable in-vivo slipperiness and taste masking times (8±1.45 and 58±2.18 seconds) respectively, with longer disintegration time (5.57±1.36 minutes) but similar release profile to the commercial conventional tablet Diovan ® with similarity factor (f2= 68.4±1.07) and difference factor (f1= 1.39± 0.95). Therefore, this study developed a new easily swallowed tablet with an efficient taste masking property, high loading capacity and adequate mechanical strength that can be used as an alternative to buccal, sublingual and orodispersible tablets.
Introduction
Dysphagia (swallowing difficulties) is a common problem in 50% of the population 1 , that making tablet swallowing undesired process for many people like pediatrics, geriatric and in case of intolerability of water like patient with allergic cough nausea or vomiting, also in case of water unavailability in traveling people 2, 3 . These difficulties accompanied with tablet swallowing generally arise from two barriers, physical and psychological barriers. Physical barriers are mainly attributed to the tablet size, shape, taste and surface, that were traditionally avoided by size reduction (≤ 8 mm in diameter), shape manipulation using oval or oblong shape, while the bad taste and the rough surface of the tablet are avoided by the application of suitable coat 4, 5 . Psychological barriers, on the other hand, are attributed to patient resistance or previous experience with a tablet sticking in the esophagus 6 . As a result, different tablet dosage forms had been developed to overcome swallowing difficulties in which drugs are administrated orally without the need of chewing or prior dispersion or dissolution in water in order to produce a systemic effect like buccal, sublingual and orodispersible tablets (ODTs) 7 .
These tablets possess many restrictions, like the prerequisite of certain properties of the drug for absorption via the mucosa of the oral cavity, not suitable for high doses, bitter and/or irritative taste or odor medications, in addition to the special packaging requirement for ODTs due to its friable and hygroscopic nature 8, 9 . Therefore, in order to alleviate the above restrictions and to overcome the previously mentioned barriers of tablets, the development of a new tablet dosage form that can offer an easily swallowing with a good taste masking property is necessary. When putting in the mouth, these tablets supposed to offer suitable taste masking along with rapid hydration ability, giving an easy slipperiness of the tablet down the GIT as intact form without water administration. These tablets called Oroslippery tablets (OSTs).
Valsartan is an antihypertensive drug belongs to the group of angiotensin receptor blockers (ARBs), with a slightly bitter or metallic taste. It is mainly used in the management of hypertension, heart failure and to reduce cardiovascular mortality in patients with left ventricular dysfunction after myocardial infarction 10, 11 .
Our work was concerned with the application of new technology to produce an easily swallowed tablet for the model drug Valsartan (160 mg) with a slippery coat (oroslippery tablet OST), that assures adequate time for tablet swallowing without disintegration in the oral cavity providing an efficient taste masking effect with immediate release profile in the GIT similar to that of the conventional tablet Diovan ® .
Materials and Methods

Materials
Valsartan, mannitol, hydroxypropyl methyl cellulose (HPMC 50 cps), magnesium stearate (Mg stearate) (Provizer pharma, India).
Crosspovidone (CP) and sodium starch glycolate (SSG) (Aladdin chemistry, China). Crosscarmellose sodium (CCS) (Samara drug industry, Iraq). Kollicoat IR (kol.) (Sigma-aldrich co., Germany).
Xanthan gum (xan.), talc, red iron oxide, titanium dioxide, peppermint oil ( Himedia, India). All other chemicals, reagents and solutions used were of analytical grade. Marketed tablet Diovan® (Novartis pharmaceutical company, Switzerland) was purchased from local pharmacy.
Methods
Preparation of the oroslippery tablets
Preparation of the core tablets
Core tablets preparation of both Valsartan and blank (drug free) tablets were performed by directly compressing the pre-weighed amount of all materials (Table 1) .The core tablets were formulated using different types and concentrations of superdisintegrants in order to determine its effects on the disintegration and dissolution of the Valsartan from the prepared tablet.
Preparation of the aqueous coating dispersion
The aqueous coating dispersion prepared in four steps:
Step 1: Preparation of pigment suspension
The red iron oxide (pigment), titanium dioxide (opacifier) and talc (anti-adherent) were suspended in distilled water with continuous stirring using magnetic stirrer at 400 rpm at room temperature for about 10 minutes until we get a homogeneous, lump free dispersion.
Step 2: Preparation of polymer solution
The film forming polymer, kollicoat IR (kol.) was added gradually with continuous stirring, in a magnetic stirrer at 100 rpm, to the aqueous solution containing mannitol as a sweetening and flavor retaining agent 13 , the stirring was done for 15 minutes at room temperature until a clear solution was obtained.
Step 3: Preparation of xanthan gum dispersion
The slipperiness inducing agent, xanthan gum (xan.) 14, 15 , was added to distilled water that was previously heated to 39 °C , to be mixed in magnetic stirrer at 600 rpm for about 5 minutes.
Step 4: Preparation of the coating dispersion This was done by the addition of the homogenized pigment suspension (step 1) after passing it through sieve number 50 (to remove any agglomeration) to the polymer solution (step 2) and mixing together in magnetic stirrer at 400 rpm, for about 5 minutes at room temperature, after that this mixture was gradually poured on the xan. dispersion (step 3), followed by adding peppermint oil with continuous stirring at 400 rpm for another 5 minutes at room temperature. Peppermint oil act as a flavoring and cooling agent 16 , which added to increase patient compliance, and also to enhance the swallowing process throughout the induction of salivation 13 and cold perception, which stimulates the trigeminal nerve that further improving the swallowing reflex 17 .
Coating of the prepared tablets
Coating was performed by dipping process, where the prepared Valsartan and blank core tablets was dipped in the coating dispersion using a suitable forceps, followed by drying at 60 °C using a hot air dryer for about 5 minutes, figure 1 represents a diagrammatic illustration of this prepared OSTs. Different coating formulas were formulated using different proportion of kol. and xan.
( . Static angle of repose were measured by the fixed base method, while Compressibility index and Hausner ratio were calculated by measurement of bulk and tapped densities 19, 20 . 
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Post compression evaluation
Physical properties
Physical properties like hardness and thickness of the prepared core and coated tablets were evaluated using three tablets, where the hardness was measured using an electrical hardness tester while thickness was measured by vernier caliper. In addition, friability and weight variation was performed according to the USP specifications 19, 21, 22 .
In-vitro disintegration
In accordance with the USP, disintegration is the condition at which no hard core were left behind on the sieve surface or attached to the lower part of the disk (if used), except for the capsule shell or the 
In-vitro release study
In-vitro dissolution of the prepared OSTs and the conventional marketed tablet (Diovan ® ) was performed using USP apparatus type II (paddle) at 37±0.5°C in 1000 ml, phosphate buffer pH 6.8 at 50 rpm 23, 24 . Five milliliters samples were periodically withdrawn, filtered and suitably diluted (on need) to be analyzed spectrophotometrically at 250 nm, the experiment was done in triplicate and the results were compared using the time required for 80% release (T80%) and percent drug released in 30 minutes (% D30min). Similarity between release profiles for the optimum formulas in comparison to the conventional marketed tablets Diovan ® was determined using both similarity factor (f2) and difference factor (f1) that were calculated using the equations below. The release profiles considered to be similar when they have (f2) values more than 50, and (f1) values less than 15 (25) .
Where, n= Number of time points, R= % drug released of the reference at time t, T= % drug release of the test at time t
In-vivo slipperiness and taste masking evaluation
All the in-vivo evaluations were approved by the ethics committee in the College of Pharmacy, Al-Mustansiriya University.
The evaluation of in-vivo slipperiness was performed to the blank (drug free) OSTs B1-B5 on five healthy human volunteers from whom informed consent was first obtained, and the time in seconds required for the blank tablets to become slippery and swallowed a whole without water was recorded and considered as an indicator to the degree of slipperiness.
And to assure that the prepared OSTs remain in intact form with an acceptable taste masking during their residence time in the mouth, taste masking effect was achieved for the selected Valsartan OSTs formulas F9-F13 by the rolling method on five healthy human volunteers who were briefly informed on the purpose of the study, after that they told to roll the OSTs gently in their oral cavity without chewing or biting and at the first sensation of a slight bitterness, they were told to spit the OSTs along with the saliva and to rinse their mouth immediately after that, the time required to feel bitterness was recorded and considered as an indicator for taste masking property for the Valsartan OST (16) . Therefore, a lower slipperiness values along with higher taste masking results were considered to be the best results.
Content uniformity
Content uniformity was applied to the optimum Valsartan OSTs 
Statistical analysis
The experiment results were expressed as an average value ± SD, and were analyzed using analysis of variance (ANOVA) single factor to compare the sample means and to determine the statistical significance, at which (p<0.05) was considered to be significant.
Results and Discussions
Pre-compression and post-compression parameters of the prepared core and coated oroslippery tablets
All measured values of angle of repose, Carr's index and Hausner ratio for the prepared core powder mixture of each formula, and its corresponding type of the flow are demonstrated in table 5, they all indicates that the prepared core mixtures had acceptable flow properties according to the USP.
Furthermore, the prepared core tablet formulas were evaluated for their physical properties, including hardness, friability, weight variation and thickness, and the results (Table 6 ) showed a nonsignificant differences between the prepared core tablets in their physical properties, with a higher tablet hardness (6.54 kg/cm Moreover, physical properties for the prepared Valsartan and blank
OSTs are illustrated in table 7. They showed non-significant differences in the hardness between the prepared OSTs with higher values observed for the blank OSTs formulas B1-B5 due to the differences in the core tablet hardness. In addition, non-significant differences were observed between the core and coated tablet hardness for formulas F1-F9 and B1, indicating that the slippery coating had no significant influence on the core tablet hardness. All the prepared OSTs had an acceptable, non-significant difference in friability with a slight improvement for OSTs formulas F12,F13,B4
and B5 which resulted from higher coating thickness in double F12,B4 and triple coating F13,B5 comparing to monolayer coating in F9,B1 consequently. Additionally, non-significant differences were detected between the OSTs weight and thickness in formulas F1-F9 indicating the reproducibility of the coating process, while a significant reduction in the weight and thickness was observed for formulas F10 and B2
containing (10% kol.+0.3% xan.) in addition to OST formulas F11
and B3 containing (15% kol.+0% xan.) comparing to F9,B1 with (15%kol.+0.3% xan.) which might be attributed to the reduction in the viscosity of the coating dispersion in these formulas, an effect which withdrawal that reduces the volume of the liquid deposited on the tablet surface leading to a thinner film layer 29, 30, 31 . On the other hand, the significant increase in the coated tablet weight and thickness which were detected in OST formulas F12,F13,B4 and B5 double and triple coated respectively with (15% kol.+0.3% xan.) comparing to F9 and B1 single coated with of (15% kol.+0.3% xan.) might be due to increasing coating thickness in double and triple coating.
In-vitro disintegration and release of the prepared oroslippery tablets
Results might be attributed to the fact that CCS possess the fastest and greatest extent of swelling in addition to its wicking effect; that resulting from its fibrous nature; causing it to act as a hydrophilic channel facilitating water uptake by the tablet 33, 34, 35 . Thus OSTs formula F9 with a core containing (6% CCS) as superdisintegrant was selected for further optimization in the coating layer.
Additionally, to demonstrate the effect of kol. concentration in the coating dispersion, OST formula F10 containing (10%kol.+0.3%xan.)
was compared with F9 containing (15%kol.+0.3%xan.) for disintegration and release ( Figure 3) . The results exhibited a significant reduction in the DT and T80% along with a significant increment in %D30min by increasing kol. concentration, which resulted mainly from the increasing the rate and extent of water uptake as a result of the hydrophilic nature of the polymer, and partially caused by the higher rate and extent of dry mass loss from the polymeric film resulting from PVA/PEG leaching from kol. upon contacting the aqueous media 36 . Results clearly revealed that raising kol. concentration from 10% in B2 to 15% in B1 led to non-significant improvement in slipperiness, while a significant improvement was observed upon increasing xan.
concentration from 0% in B3 to 0.3% in B1 respectively, which signifying the importance of xan. as slipperiness inducer to facilitate the swallowing process of the prepared tablets. On the other hand, a significant increase in taste masking property was observed at the higher concentration of both kol. and xan. in F9 (15% kol.+0.3%
xan.) comparing to F10 with (10% kol.+0.3 xan.) and F11 with (15%kol.+0% xan.). These results might be due to the greater viscosity of the coating dispersion that observed by the higher kol.
and xan. concentrations in B1 and F9, which increased the hydrodynamic drag of the coating dispersion that finally gave a higher coat thickness. 
Comparison of the optimum prepared Valsartan oroslippery tablets with the conventional marketed tablet (Diovan ® )
A comparison between the optimum formula F12 and conventional marketed tablet Diovan ® in DT and release profile in phosphate buffer pH 6.8 were done and the results are illustrated in figure (6) .
The result showed that although a little significant increase in the DT was observed in F12, it had no significant influence on the release profile represented by T80% and % D30min (Figure 7 ). This was assured by the calculation of the difference factor (f1) and the similarity factor (f2) for optimum Valsartan OSTs by considering Diovan ® tablet as a reference. The f1 was found to be less than 15
(1.39±0.95), while the f2 was more than 50 (68.4±1.07) in phosphate buffer pH 6.8, indicating that the prepared OSTs formula F12 had a similar release profile to the conventional marketed tablet Diovan ® but with longer DT in order to assure no disintegration occurs in the mouth before swallowing through slipperiness mechanism. 
Drug excipients compatibility
The FTIR spectrum for the grinded core and coated OSTs for the optimum formula F12 in addition to the Valsartan pure powder showed the same characteristic peaks with no significant shifting in the peaks, indicating that no interaction occurred between the drug and other components of the prepared OSTs.
The peak at 3414 cm -1 indicated the prescence of N-H and O-H streching, while the peak at 2964 cm -1 resulted from aliphatic C-H streching. The characteristic peak at 1732cm -1 representing the carboxylic acid C=O streching, whereas the C=N streching caused the peak at 1602 cm 
Conclusions
In this study, it was possible to prepare and optimize tablets with slippery coating that is easily swallowed without affecting drug release (immediate release) and doesn't disintegrate in the mouth (un-like ODTs) with an acceptable taste masking property. This new technology facilitates the swallowing of large circular shape tablet by the application of slippery coating in an attempt for reducing both physical and psychological barrier for tablets, furthermore it offers a new easy to handle tablet dosage form with higher flexibility for drug and dose selection and lower taste masking difficulties than buccal, SL and ODTs.
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